Lineage Cell Therapeutics, Inc. (LCTX)

0.9541 -0.0432 (-4.33%) 收市：04:00PM EDT

Lineage Cell Therapeutics, Inc.

2173 Salk Avenue
Suite 200
Carlsbad, CA 92008
United States
442 287 8990
https://www.lineagecell.com

版塊: Healthcare
行業: Biotechnology
全職員工: 68

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Brian M. Culley M.A., M.B.A.	CEO, President & Director	986.7k	無	1971
Ms. Jill Ann Howe	CFO & Principal Financial and Accounting Officer	587.4k	無	1976
Mr. George A. Samuel III, J.D.	General Counsel & Company Secretary	554.51k	無	1981
Ioana C. Hone	Director of Investor Relations	無	無	無
Dr. Charlotte Hubbert Ph.D.	Vice President of Corporate Development	無	無	無
Ms. Brandi L. Roberts CPA, M.B.A.	Consultant	407.45k	無	1974
Mr. William Annett MBA	President & CEO of OncoCyte Corporation	53.2k	無	1954
Dr. Rami Skaliter Ph.D.	Chief Executive Officer of Cell Cure Neurosciences	無	無	1958
Ms. Alexandra Hernandez	Senior Director of Finance & Controller	無	無	無
Dr. Harold D. Waitz	Vice President of Regulatory Affairs & Quality Control	90k	無	1942

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

公司管治

截至 2024年6月29日 止，Lineage Cell Therapeutics, Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：2；董事會：7；股東權利：2；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。